依达拉奉对急性脑梗死神经功能的保护作用  

Effect of edaravone on acute cerebral infarction

作　　者：贾春红[1] 张鸿[1] 

机构地区：[1]中国医科大学附属盛京医院神经内科,沈阳110004

出　　处：《实用药物与临床》2009年第1期11-12,共2页Practical Pharmacy and Clinical Remedies

摘　　要：目的探讨依达拉奉(Edaravone)治疗急性脑梗死的临床疗效。方法采用随机对照试验,选择发病48h内的ACI患者56例,随机分为治疗组(28例)及对照组(28例)。对照组用银杏达莫注射液+肠溶阿司匹林,治疗组在常规治疗的基础上加用依达拉奉30mg,每日2次,静脉滴注,疗程均为14d。分别在治疗前、治疗14d进行美国国立卫生研究院卒中量表(NIHSS)和日常生活活动能力量表(BI)指数评分。结果14d后治疗组、对照组NIHSS、ADL相比差异有统计学意义(P<0.05),两组无明显不良反应。结论依达拉奉能有效改善急性脑梗死的神经功能缺失和日常生活活动能力,无明显不良反应。临床疗效好,安全性高。Objective To evaluate the efficacy of edaravone in treatment of acute cerebral infarction （ACI）. Methods A randomized controlled study was carried out,56 patients with ACI enrolled within 48 hours of onset were randomly allocated into treatment group（ n = 28 ）and control group（ n = 28 ）. Patients in both groups were given Yinxingdamo injection and aspirin 100 mg orally once per day. Patients in treatment group also received edaravone injection 30 mg twice per day for 14 days. The neurological deficits and activities of daily living（ADL） of patients in both groups were assessed by using national institute of health stroke scale（ NIHSS ）and Barthel Index respectively before and after the treatment. Clinical efficacy was evaluated according to changes of NIHSS and ADL scores on the 14 th day. Results There were significant differences in NIHSS scores and ADL scores between the 2 groups（P 〈0. 05）. There was no distinct adverse reaction in the 2 groups. Conclusion Edaravone can improve impaired neurological function and activities of daily living in patients with acute cerebral infarction without obviously adverse reaction, it is effective and safe.

关 键 词：急性脑梗死 依达拉奉 自由基清除剂 

分 类 号：R743.3[医药卫生—神经病学与精神病学]